Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children

Launched by INSTITUTE OF LIVER AND BILIARY SCIENCES, INDIA · Nov 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different schedules for a treatment called plasma exchange in children with Wilson disease who are experiencing acute liver failure. Wilson disease is a condition that causes copper to build up in the body, which can lead to serious health issues, including liver failure. The trial will compare daily plasma exchange treatment to alternate-day treatment to see which schedule is more effective at removing excess copper from the blood and improving patient outcomes.

To be eligible for this trial, children aged 3 to 18 years must have Wilson disease and meet certain health criteria, such as having a specific score indicating the severity of their condition. However, children with severe brain swelling or other serious health issues won't be included. Participants can expect to receive plasma exchange treatments, which help quickly remove harmful substances from the blood. This trial aims to find the best way to help these children, potentially improving their chances of recovery and overall health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Wilson disease with New Wilson Index of ≥ 11 and INR ≥ 2.5
• • 2. Children aged 3 years to 18 years
• Exclusion Criteria:
• • 1. Grade 3 or grade 4 hepatic encephalopathy
• • 2. Septic shock
• • 3. Disseminated intravascular coagulation
• • 4. Marked hemodynamic instability requiring a high dose of vasopressors (norepinephrine \>0.5 mcg/kg/min)
• • 5. Any severe cardio-pulmonary pre-existing disease